2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4530 Fracture risk following R-CHOP therapy in patients with diffuse large B-cell lymphoma: A nationwide population-based cohort study

Hyeon Gyu Cho, MD, Sun Young Jeong2, Dongwoo Kang, BS3, Min-Young Lee4, Namsu Lee5, Jong-Ho Won6, Kyoung Ha Kim, MD, PhD7, Seug Yun Yoon, MD, PhD8
1 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
2 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
3 Hanmi Pharm. Co., Ltd, Seoul, Korea, Rep. of South
4 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
5 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
6 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
7 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South
8 Soonchunhyang University Seoul Hospital, Seoul, Korea, Rep. of South

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard first-line therapy. Repeated exposure to high-dose corticosteroids, together with treatment-related endocrine dysfunction, reduced physical activity, and systemic inflammation, may accelerate bone loss and increase fracture risk. Although previous studies have reported an increased incidence of fractures following R-CHOP therapy, evidence has largely been derived from selected patient populations, and the magnitude of excess fracture risk compared with the general population remains uncertain. We therefore conducted a nationwide matched cohort study to compare fracture risk between patients with DLBCL treated with R-CHOP and matched non-cancer controls and to explore clinical risk factors for fractures among patients with DLBCL.

Methods

We conducted a nationwide retrospective matched cohort study using the Korean National Health Insurance claims database. A total of 23,347 patients with newly diagnosed DLBCL who received first-line R-CHOP between January 1, 2003, and December 31, 2020, were matched 1:1 with 23,347 individuals without DLBCL using propensity scores based on demographic characteristics and baseline comorbidities. Cumulative incidences of vertebral, hip, upper-limb, and overall fractures were compared using Kaplan–Meier analysis and the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. The primary analysis used a fully adjusted multivariable model accounting for demographic characteristics, lifestyle factors, baseline comorbidities, osteoporosis, bone-modifying agent use, and comorbidity burden. Potential clinical risk factors for fracture among patients with DLBCL, including age, sex, osteoporosis, and baseline bisphosphonate use, were also evaluated.

Results

After propensity score matching, baseline characteristics were well balanced between groups (all standardized mean differences <0.1). During follow-up, the incidence of any fracture was higher in patients with DLBCL than in matched controls (19.7 vs. 16.3 per 1,000 person-years), with the greatest absolute difference observed for vertebral fractures (10.7 vs. 8.2 per 1,000 person-years). In the fully adjusted Cox model, DLBCL remained independently associated with an increased risk of any fracture (adjusted hazard ratio [aHR] 1.29, 95% CI 1.00–1.65; P=0.046) and vertebral fracture (aHR 1.42, 95% CI 1.03–1.97; P=0.034), whereas the associations with hip fracture and upper-limb fracture were not statistically significant after full adjustment. Among patients with DLBCL, older age (≥65 years) and female sex were consistently associated with a higher risk of fracture, whereas the associations with osteoporosis and bisphosphonate use were attenuated after adjustment for comorbidities and other covariates.

Conclusions

Patients with DLBCL treated with R-CHOP have a significantly increased risk of fractures, particularly vertebral fractures, compared with matched non-cancer controls. Older age and female sex were identified as major clinical risk factors for fracture among patients with DLBCL. These findings support routine bone health assessment and implementation of fracture prevention strategies as part of survivorship care in patients receiving R-CHOP.
Hyeon Gyu Cho, MD: No relevant conflicts of interest to declare.